The group's principal activities are the research, development, manufacture and commercialization of cancer therapeutics and cancer diagnostics and licensing. This is done through a series of proprietary platform technologies using monoclonal antibodies. The group operates in two segments namely, contract manufacturing and licensing. The group is focussing on the development of its collateral targeting antibody based technologies, 'collateral targeting agents'. The services include contract manufacturing of antibodies and proteins, cell culture development, process development, and testing of biologics for biopharmaceutical and biotechnology companies.
